KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash from Financing Activities (2016 - 2025)

Vertex Pharmaceuticals has reported Cash from Financing Activities over the past 17 years, most recently at -$77.2 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at -$77.2 million for Q4 2025, up 80.27% from a year ago — trailing twelve months through Dec 2025 was -$2.3 billion (down 51.27% YoY), and the annual figure for FY2025 was -$2.3 billion, down 51.27%.
  • Cash from Financing Activities for Q4 2025 was -$77.2 million at Vertex Pharmaceuticals, up from -$1.2 billion in the prior quarter.
  • Over the last five years, Cash from Financing Activities for VRTX hit a ceiling of $47.7 million in Q2 2022 and a floor of -$1.2 billion in Q3 2025.
  • Median Cash from Financing Activities over the past 5 years was -$315.4 million (2021), compared with a mean of -$293.2 million.
  • Biggest five-year swings in Cash from Financing Activities: surged 111.96% in 2022 and later crashed 2172.83% in 2024.
  • Vertex Pharmaceuticals' Cash from Financing Activities stood at -$336.2 million in 2021, then soared by 111.96% to $40.2 million in 2022, then tumbled by 398.01% to -$119.8 million in 2023, then crashed by 226.63% to -$391.3 million in 2024, then surged by 80.27% to -$77.2 million in 2025.
  • The last three reported values for Cash from Financing Activities were -$77.2 million (Q4 2025), -$1.2 billion (Q3 2025), and -$349.2 million (Q2 2025) per Business Quant data.